These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 34502204)

  • 1. Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients.
    Kulikowska de Nałęcz A; Ciszak L; Usnarska-Zubkiewicz L; Frydecka I; Pawlak E; Szmyrka M; Kosmaczewska A
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inappropriate Expression of PD-1 and CTLA-4 Checkpoints in Myeloma Patients Is More Pronounced at Diagnosis: Implications for Time to Progression and Response to Therapeutic Checkpoint Inhibitors.
    Kulikowska de Nałęcz A; Ciszak L; Usnarska-Zubkiewicz L; Pawlak E; Frydecka I; Szmyrka M; Kosmaczewska A
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4
    Alrasheed N; Lee L; Ghorani E; Henry JY; Conde L; Chin M; Galas-Filipowicz D; Furness AJS; Chavda SJ; Richards H; De-Silva D; Cohen OC; Patel D; Brooks A; Rodriguez-Justo M; Pule M; Herrero J; Quezada SA; Yong KL
    Clin Cancer Res; 2020 Jul; 26(13):3443-3454. PubMed ID: 32220887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab modifies regulatory T cells and co-inhibitory receptor expression on circulating T cells in psoriasis.
    Yu Y; Chen Z; Wang Y; Li Y; Lu J; Cui L; Yu Z; Ding Y; Guo C; Zhang X; Shi Y
    Int Immunopharmacol; 2021 Jul; 96():107722. PubMed ID: 33965878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint inhibitors for cancer treatment.
    Park J; Kwon M; Shin EC
    Arch Pharm Res; 2016 Nov; 39(11):1577-1587. PubMed ID: 27770382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.
    Langhans B; Nischalke HD; Krämer B; Dold L; Lutz P; Mohr R; Vogt A; Toma M; Eis-Hübinger AM; Nattermann J; Strassburg CP; Gonzalez-Carmona MA; Spengler U
    Cancer Immunol Immunother; 2019 Dec; 68(12):2055-2066. PubMed ID: 31724091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers.
    Palma M; Gentilcore G; Heimersson K; Mozaffari F; Näsman-Glaser B; Young E; Rosenquist R; Hansson L; Österborg A; Mellstedt H
    Haematologica; 2017 Mar; 102(3):562-572. PubMed ID: 27927767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab.
    Kwek SS; Lewis J; Zhang L; Weinberg V; Greaney SK; Harzstark AL; Lin AM; Ryan CJ; Small EJ; Fong L
    Cancer Immunol Res; 2015 Sep; 3(9):1008-16. PubMed ID: 25968455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreased Expression of Negative Immune Checkpoint VISTA by CD4+ T Cells Facilitates T Helper 1, T Helper 17, and T Follicular Helper Lineage Differentiation in GCA.
    Hid Cadena R; Reitsema RD; Huitema MG; van Sleen Y; van der Geest KSM; Heeringa P; Boots AMH; Abdulahad WH; Brouwer E
    Front Immunol; 2019; 10():1638. PubMed ID: 31379838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway.
    Chen D; Tang P; Liu L; Wang F; Xing H; Sun L; Jiang Z
    Cell Cycle; 2018; 17(7):858-867. PubMed ID: 29493401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treg-mediated acquired resistance to immune checkpoint inhibitors.
    Saleh R; Elkord E
    Cancer Lett; 2019 Aug; 457():168-179. PubMed ID: 31078738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma.
    Lee L; Alrasheed N; Khandelwal G; Fitzsimons E; Richards H; Wilson W; Chavda SJ; Henry J; Conde L; De Massy MR; Chin M; Galas-Filipowicz D; Herrero J; Chain B; Quezada SA; Yong K
    Front Immunol; 2021; 12():618610. PubMed ID: 33717112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal Expression of BTLA and CTLA-4 Immune Checkpoint Molecules in Chronic Lymphocytic Leukemia Patients.
    Karabon L; Partyka A; Ciszak L; Pawlak-Adamska E; Tomkiewicz A; Bojarska-Junak A; Roliński J; Wołowiec D; Wrobel T; Frydecka I; Kosmaczewska A
    J Immunol Res; 2020; 2020():6545921. PubMed ID: 32775467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-21 Participates in the PD-1/PD-L1 Pathway-Mediated Imbalance of Th17/Treg Cells in Patients After Gastric Cancer Resection.
    Zheng X; Dong L; Wang K; Zou H; Zhao S; Wang Y; Wang G
    Ann Surg Oncol; 2019 Mar; 26(3):884-893. PubMed ID: 30565043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of immune checkpoints in T cells of esophageal cancer patients.
    Xie J; Wang J; Cheng Sh; Zheng L; Ji F; Yang L; Zhang Y; Ji H
    Oncotarget; 2016 Sep; 7(39):63669-63678. PubMed ID: 27577071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer.
    Taylor NA; Vick SC; Iglesia MD; Brickey WJ; Midkiff BR; McKinnon KP; Reisdorf S; Anders CK; Carey LA; Parker JS; Perou CM; Vincent BG; Serody JS
    J Clin Invest; 2017 Sep; 127(9):3472-3483. PubMed ID: 28825599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
    Kumagai S; Togashi Y; Kamada T; Sugiyama E; Nishinakamura H; Takeuchi Y; Vitaly K; Itahashi K; Maeda Y; Matsui S; Shibahara T; Yamashita Y; Irie T; Tsuge A; Fukuoka S; Kawazoe A; Udagawa H; Kirita K; Aokage K; Ishii G; Kuwata T; Nakama K; Kawazu M; Ueno T; Yamazaki N; Goto K; Tsuboi M; Mano H; Doi T; Shitara K; Nishikawa H
    Nat Immunol; 2020 Nov; 21(11):1346-1358. PubMed ID: 32868929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1 has a unique capacity to inhibit allergen-specific human CD4
    Rosskopf S; Jahn-Schmid B; Schmetterer KG; Zlabinger GJ; Steinberger P
    Sci Rep; 2018 Sep; 8(1):13543. PubMed ID: 30201974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.